Sunshine Biopharma (SBFM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,784 | -1,660 | -2,156 | -1,040 | -3,497 |
| Depreciation Amortization | 14 | 14 | 49 | 7 | 617 |
| Accounts receivable | -2 | 0 | -15 | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | N/A | -80 |
| Other Working Capital | -43 | -31 | 55 | -17 | -91 |
| Other Operating Activity | 2,157 | 1,182 | 1,555 | 507 | 2,736 |
| Operating Cash Flow | $-657 | $-496 | $-513 | $-544 | $-314 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1 | -1 | -19 | -4 | -3 |
| Net Acquisitions | N/A | N/A | 5 | -80 | N/A |
| Other Investing Activity | 0 | -14 | 0 | 0 | 0 |
| Investing Cash Flow | $-1 | $-15 | $-14 | $-84 | $-3 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 28 | 19 | 25 | N/A |
| Debt Issued | 1,674 | 441 | 667 | 697 | 198 |
| Debt Repayment | -107 | -53 | -194 | -115 | N/A |
| Common Stock Issued | N/A | N/A | N/A | 64 | 104 |
| Other Financing Activity | 41 | 26 | 36 | 0 | 22 |
| Financing Cash Flow | $1,608 | $442 | $528 | $671 | $325 |
| Exchange Rate Effect | 0 | -6 | 7 | 7 | 0 |
| Beginning Cash Position | 41 | 115 | 108 | 58 | 51 |
| End Cash Position | 990 | 41 | 115 | 108 | 58 |
| Net Cash Flow | $950 | $-75 | $1 | $43 | $7 |
| Free Cash Flow | |||||
| Operating Cash Flow | -657 | -496 | -513 | -544 | -314 |
| Capital Expenditure | -1 | -1 | -19 | -4 | -3 |
| Free Cash Flow | -659 | -497 | -532 | -547 | -318 |